Abstract
BackgroundAssessing cfDNA at a whole-exome scale (WES) enables comprehensive immunogenomic profiling and interrogation of tumor heterogeneity. We comprehensively investigate genomic alterations and neoantigens in cfDNA at WES-scale using Personalis’ NeXT...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have